ClinicalTrials.gg
RecruitingNCT07400939Updated May 12, 2026

Brain Stimulation Combined With Watching Hand Movements to Improve Hand Recovery in Chronic Stroke

An interventional study of tDCS and Action Observation Therapy (AOT) in Stroke, tDCS and Action Observation Therapy, sponsored by Universiti Malaysia Sabah. Recruiting at 2 sites in Malaysia. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Universiti Malaysia Sabah · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Stroke with a site in Malaysia — 6 open to participants now, 8 under way, 2 of them phase 3. Stroke · Malaysia.

Planned enrollment
29th of 40
60 · median 345
Started
2026
with 2 others
No phase
18 of 45
4 open now
Registered
41st of 45
by date

Among the 45 studies in Stroke with a site in Malaysia, this one is the 29th largest by planned enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2026, is one of 18 with no phase, and was the 41st registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

6 of the 45 studies in Stroke with a site in Malaysia are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Malaysia have not opened yet or have stopped. Only those recruiting at a site in Malaysia →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Stroke with a site in Malaysia, or all of them as a file.
02

Study summary

This study investigates the neurophysiological mechanisms underlying the combined use of transcranial direct current stimulation (tDCS) and action observation therapy (AOT) for hand motor recovery in individuals with stroke. Background: While both tDCS and AOT have shown promise individually for stroke rehabilitation, the neural mechanisms of their combined effects remain unclear. Understanding these mechanisms could optimise rehabilitation protocols and improve functional outcomes. Intervention: Participants will receive 10 sessions of anodal tDCS over the ipsilesional motor cortex combined with AOT over two weeks in a clinical setting, followed by 8 weeks of home-based AOT practice. Control groups will receive tDCS alone or AOT alone. Neurophysiological changes will be assessed using motor evoked potentials (MEPs) to evaluate corticospinal excitability. Clinical hand function will be assessed using standardised outcome measures. Measurements: Assessments will be conducted at baseline, during intervention (week 2), and after the home practice phase (week 10) to evaluate neuroplastic changes. Significance: This study will provide mechanistic insights into how neuromodulation and observational learning interact to promote motor recovery, informing evidence-based rehabilitation strategies for stroke survivors in Malaysia and globally. Study Design: Randomised controlled trial with three parallel arms, recruiting 60 participants with chronic stroke from Sabah, Malaysia.

Read the detailed description

The participation duration for each participant is 10 weeks, including the assessment period.

Group 1 tDCS + AOT (intervention): tDCS will be administered at the outpatient clinic for 20 minutes per session, for a total of 10 sessions over two consecutive weeks. During the tDCS sessions, each participant will engage in AOT for 30 minutes under the supervision of a therapist. Subsequently, each participant will continue performing AOT at home for 30 minutes per session, once a day, five days per week, for 8 consecutive weeks.

Group 2 tDCS alone (control): tDCS will be administered at the outpatient clinic for 20 minutes per session, for a total of 10 sessions over two consecutive weeks. During the tDCS sessions, each participant will watch a landscape video for 30 minutes. Subsequently, each patient will continue watching the landscape video at home for 30 minutes per session, once a day, five days per week, for 8 consecutive weeks.

Group 3 AOT alone (control): placebo tDCS will be administered at the outpatient clinic for 20 minutes per session, for a total of 10 sessions over 2 consecutive weeks. During the placebo tDCS sessions, each participant will engage in AOT for 30 minutes under the supervision of a therapist. Following the clinic sessions, each patient will continue performing AOT at home for 30 minutes per session, once a day, five days per week, for 8 consecutive weeks.

The principal investigator will visit each research site throughout the duration of the study. All participants will attend the outpatient rehabilitation setting five times a week for 30 minutes per session, for 2 consecutive weeks, and continue intervention at home for five days a week for 8 consecutive weeks. The total intervention duration consists of 10 consecutive weeks. For each session in the hospital, there will be a physiotherapist to monitor participants' compliance with the interventions and to ensure that the training is conducted as per protocol. Level of participation would be measured by Rating of Perceived Exertion Scale of 3-5 (light activity to somewhat hard). If the subject attended the session but refuse to participate in the intervention, the subject would be excluded from the study.

03

Conditions studied

  • Stroke
  • tDCS
  • Action Observation Therapy
  • Hand
  • Motor Evoked Potential
  • EMG
  • Neuroplasticity
  • Neurophysiological Assessment

Browse trials for

Keywords

  • stroke rehabilitation
  • transcranial direct current stimulation
  • action observation therapy
  • neuroplasticity
  • neurophysiological
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 59 years
  • Single episode of unilateral stroke and weakness in hand muscles 6 to 24 months post-stroke
  • No excessive spasticity of the upper limb, defined as grade two or less on Modified Ashworth Scale

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with posterior circulation infarction
  • Unable to follow commands due to poor cognitive function
  • Unilateral neglect
  • Homonymous hemianopia
  • Other existing neurological disorders that lead to poor hand function
  • Grade four or five hand muscle strength.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Active tDCS + AOT

    Participants will receive anodal transcranial direct current stimulation (tDCS) at 2 mA for 20 minutes combined with action observation therapy (AOT) for 10 sessions over 2 weeks at an outpatient clinic. During tDCS delivery, participants will observe first-person perspective videos of hand motor tasks and practice the observed movements. Following the clinic phase, participants will continue AOT practice at home for 30 minutes once daily for 8 weeks.

    Other: tDCS · Other: Action Observation Therapy (AOT)

  • Placebo comparator
    sham tDCS + AOT

    Sham tDCS group - apply sham anodal tDCS with a 30s ramp-up and 30s ramp-down, switching the current to 0mA without the participant's awareness. Administer sham anodal tDCS for 20 minutes. Concurrently perform AOT for 30 minutes.

    Other: Action Observation Therapy (AOT)

  • Active comparator
    tDCS only

    Administer active anodal tDCS for 20 minutes. Concurrently perform upper limb motor task actions with landscape video for 30 minutes.

    Other: tDCS

Interventions

  • OthertDCS

    * Stimulation type: Anodal stimulation * Electrode size: 5x7cm * Stimulation target: C3/C4 primary motor cortex (M1) based on the 10-20 international electroencephalography system * Stimulation intensity: 2 mA * Stimulation current density: 0.029-0.057 mA/cm2 Use tDCS with two saline-soaked surface sponge electrodes (5x7cm) applied to the scalp, secured with a headband. Stimulation intensity is set to 2mA, with 30s ramping up at the start and 30s ramping down at the end of stimulation.

  • OtherAction Observation Therapy (AOT)

    Participants watch selected videos based on muscle grading of triceps, which include functional movement patterns and daily activity tasks of the upper limb. These videos are presented through a computer or mobile screen positioned at an appropriate distance from the participant to allow ample space for performing the required movements.

06

What researchers measure

Primary outcomes

  1. Motor Evoked Potentials (MEPs)

    Peak-to-peak amplitude of motor evoked potentials (MEPs) elicited by single-pulse transcranial magnetic stimulation (TMS) and recorded via surface electromyography (EMG) from hand muscles of the paretic upper limb. Assessment Method: * TMS delivers single pulses over ipsilesional primary motor cortex (M1 hand area) * Surface EMG electrodes record responses from first dorsal interosseous (FDI), abductor pollicis brevis (APB), and extensor carpi radialis (ECR) muscles * Motor hotspot identified (optimal scalp location producing largest MEPs) * Resting motor threshold determined * 15-20 MEPs recorded at 120% of resting motor threshold * Inter-stimulus interval: 5-7 seconds * MEP amplitude measured as peak-to-peak voltage in millivolts (mV)

    Time frame: From enrolment to the end of treatment at 10 weeks

07

Study locations

2 of 2 sites recruiting
  • Hospital Universiti Malaysia Sabah (HUMS)
    Kota Kinabalu, Sabah 88400, Malaysia
    Recruiting
  • Queen Elizabeth Hospital
    Kota Kinabalu, Sabah 88586, Malaysia
    Enrolling by invitation
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 9 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 9 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 10, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Jan 20, 2027
CompletionEst.
Jan 20, 2028
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07400939
Lead sponsor
Universiti Malaysia Sabah
Responsible party
Candace Goh Xiao Huey (Principal Investigator, Universiti Malaysia Sabah) — Principal investigator
First posted
Feb 10, 2026
Start date
Apr 1, 2026
Primary completion
Jan 20, 2027 (estimated)
Completion
Jan 20, 2028 (estimated)
Last update
May 12, 2026

Study contacts

Candace Goh Xiao Huey, Msc.
Contact
candace@moh.gov.my
+60-162316345
Fatimah Ahmedy, MRehabMed
Contact
fatimahmedy@ums.edu.my
+60-138805513
Fatimah Ahmedy
principal investigator · Universit Malaysia Sabah

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion